Perry, M.E., Stirling, A. and Hunter, J.A. (2007) Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clinical Rheumatology, 27, 923-925. doi:10.1007/s10067-008-0875-3

has been cited by the following article:

• TITLE: Clinical management of gastrointestinal amyloidosis

  AUTHORS: Hajime Isomoto, Yasuhiro Kamo, Chun Chuan Chen, Kazuhiko Nakao

  KEYWORDS: Gastrointestinal Amyloidosis; Secondary Amyloidosis; Epidermolysis Bullosa; Colchicine

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.2 No.4, November 29, 2012

  ABSTRACT: Amyloidosis is characterized by extracellular deposition of abnormal protein, consisting of primary, secondary, hemodialysis-related, hereditary, senile and localized type. Primary amyloidosis is associated with monoclonal light chains. Secondary amyloidosis is associated with inflammatory, infectious, and neoplastic diseases. Amyloid deposition in the gastrointestinal tract can manifest the symptoms including diarrhea, steatorrhea, or constipation. For diagnosis, one should obtain an immunofixation of serum or urine as well as biopsy sampling of gastrointestinal mucosa stained specifically. While most gastrointestinal complications are managed symptomatically, treatment depends upon the type of amyloidosis. Causal therapy is reserved for a select few from various subtypes of this disorder.